Cook Jennifer E. 4

What Happened

• Jennifer E. Cook, a director of Denali Therapeutics, received equity awards on June 3, 2026: 6,408 restricted stock units (RSUs) and a 19,226-share derivative award (option-type grant). Both awards were reported at $0.00 (no cash paid).
• The RSUs are unvested and the derivative award is a time‑based grant; neither represents immediately tradable shares until vesting (and options, if applicable, would require exercise).

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (appears timely).
• Reported amounts/prices: 6,408 RSUs @ $0.00; 19,226 derivative award @ $0.00.
• Shares owned following the transaction: not specified in the information provided.
• Notable footnotes:
  • F1: Each RSU represents a contingent right to one share; 100% of these RSUs vest on the earlier of (i) one year after grant or (ii) the day before the issuer’s next annual stockholder meeting.
  • F2: Confirms the 6,408 RSUs are unvested.
  • F3: The derivative (option) award vests 100% on the same schedule as above (one‑year anniversary or day before next annual meeting).
• Filing timeliness: Form 4 was filed two days after the grant date, which is within the standard reporting window (no late filing indicated).

Context

• These grants appear to be compensation/retention awards to a board member rather than an open‑market purchase or sale; such awards are common and do not, by themselves, indicate an insider buying or selling stock.
• RSUs convert to shares only after vesting and any required delivery conditions; option-style awards require exercise (and possibly payment of an exercise price, which is not disclosed in the provided filing) before becoming shares.